ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Contrary to our results, a study in Ecuador showed that ~95% of CML patients with BCR-ABL have major b2a2 breakpoint and only 5.4% are major b3a2 breakpoint.